-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the acceleration of new drug approval and review, the advancement of medical insurance policies, and the gradual improvement of the innovative drug policy system, China's innovative drug industry has developed rapidly, and new drug products have been continuously launched
.
Data show that in 2018, the scale of China's innovative drug market has exceeded 100 billion yuan, and it is expected to reach 250 billion yuan by 2023
.
It is worth mentioning that for the pharmaceutical companies with the layout, the new drugs will also face challenges such as competition from competing products and price reductions in centralized procurement.
In this regard, the industry believes that they have commercialization capabilities, reasonable layout of pipelines under development, and strong R&D capabilities.
Companies are better able to meet challenges and meet more clinical needs through differentiated competitive advantages
.
For an innovative pharmaceutical company, the strength of its R&D investment, estimated pipeline sales, and innovative drug revenue determine the company's "innovation index"
.
It is reported that Simcere attaches great importance to and is committed to the research and development of innovative drugs.
It is guided by clinical value, insists on differentiation, continuously strengthens target layout and product portfolio in strategically focused areas, and continues to explore patients urgently needed and has huge market potential.
's products
.
According to the 2021 annual report released by Simcere Pharmaceuticals recently, during the reporting period, the company achieved a total revenue of about 5 billion yuan and a profit of 1.
499 billion yuan, a year-on-year increase of 125.
6%
.
Among them, the revenue growth of innovative drugs was strong, an increase of 53.
8% over the same period in 2020, and the revenue reached 3.
120 billion yuan
.
In 2021, the proportion of innovative drug revenue to total revenue in the same period reached a new high, reaching 62.
4% (the proportions were 32.
9% and 45.
1% in 2019 and 2020, respectively)
.
At the same time, Simcere will invest 1.
417 billion yuan in research and development in 2021, accounting for 28.
3% of its total revenue, which also hit a record high
.
The announcement shows that the increase in total revenue in 2021 is mainly due to the rapid revenue growth brought by the innovative drug Xianbisxin (Edaravone Dexbornol Injection Concentrated Solution)
.
This product is a class of innovative drugs with independent intellectual property rights developed by Simcere Pharmaceuticals, and was approved for marketing on July 30, 2020 for the treatment of ischemic stroke
.
On December 28 of the same year, Xabixin was included in the National Medical Insurance Drug List (2020)
.
After the drug entered the medical insurance, the sales volume increased rapidly
.
Simcere Pharma's interim performance report shows that the revenue of the drug portfolio for central nervous system diseases (main products are Xianbisxin and Bizun) reached RMB 595 million, accounting for 28.
1% of the total revenue.
Among the three major therapeutic areas of "autoimmunity", Xianbixin's contribution is particularly prominent
.
According to reports, the company's research and development focus is mainly on the fields of tumor, nervous system and autoimmunity, and at the same time, it is forward-looking in the field of diseases that will have great influence in the future
.
Among them, in the field of nervous system, in addition to the two products of Xianbisin and Bicun, there are also Xianbexin sublingual tablets (a solid preparation composed of two active ingredients, edaravone and d-camphenol) under development.
expected
.
It is understood that the product can exert anti-inflammatory and improve the permeability of the blood-brain barrier through sublingual administration, thereby reducing the cranial nerve damage caused by acute ischemic stroke (AIS).
Sequential therapy is beneficial for patients to obtain a timely and complete course of treatment.
At the same time, sublingual tablets are not limited by medical site conditions and patient compliance, and are also more suitable for expanding other chronic central nervous system disease indications
.
As of the date of this announcement, the Group has nearly 60 innovative drug R&D pipeline projects and 19 innovative drug pipelines in the clinical stage, including 7 Phase III clinical trials, 5 Phase II clinical trials and 7 Phase I clinical trials
.
Among them, the conditional listing application of tralacil hydrochloride for injection has been submitted by the end of 2021 and has been included in the priority review; the progress of the phase III pivotal clinical trial of Xianbixin sublingual tablet has exceeded expectations, and it is expected to complete all enrollment in the first half of 2022 plan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Data show that in 2018, the scale of China's innovative drug market has exceeded 100 billion yuan, and it is expected to reach 250 billion yuan by 2023
.
It is worth mentioning that for the pharmaceutical companies with the layout, the new drugs will also face challenges such as competition from competing products and price reductions in centralized procurement.
In this regard, the industry believes that they have commercialization capabilities, reasonable layout of pipelines under development, and strong R&D capabilities.
Companies are better able to meet challenges and meet more clinical needs through differentiated competitive advantages
.
For an innovative pharmaceutical company, the strength of its R&D investment, estimated pipeline sales, and innovative drug revenue determine the company's "innovation index"
.
It is reported that Simcere attaches great importance to and is committed to the research and development of innovative drugs.
It is guided by clinical value, insists on differentiation, continuously strengthens target layout and product portfolio in strategically focused areas, and continues to explore patients urgently needed and has huge market potential.
's products
.
According to the 2021 annual report released by Simcere Pharmaceuticals recently, during the reporting period, the company achieved a total revenue of about 5 billion yuan and a profit of 1.
499 billion yuan, a year-on-year increase of 125.
6%
.
Among them, the revenue growth of innovative drugs was strong, an increase of 53.
8% over the same period in 2020, and the revenue reached 3.
120 billion yuan
.
In 2021, the proportion of innovative drug revenue to total revenue in the same period reached a new high, reaching 62.
4% (the proportions were 32.
9% and 45.
1% in 2019 and 2020, respectively)
.
At the same time, Simcere will invest 1.
417 billion yuan in research and development in 2021, accounting for 28.
3% of its total revenue, which also hit a record high
.
The announcement shows that the increase in total revenue in 2021 is mainly due to the rapid revenue growth brought by the innovative drug Xianbisxin (Edaravone Dexbornol Injection Concentrated Solution)
.
This product is a class of innovative drugs with independent intellectual property rights developed by Simcere Pharmaceuticals, and was approved for marketing on July 30, 2020 for the treatment of ischemic stroke
.
On December 28 of the same year, Xabixin was included in the National Medical Insurance Drug List (2020)
.
After the drug entered the medical insurance, the sales volume increased rapidly
.
Simcere Pharma's interim performance report shows that the revenue of the drug portfolio for central nervous system diseases (main products are Xianbisxin and Bizun) reached RMB 595 million, accounting for 28.
1% of the total revenue.
Among the three major therapeutic areas of "autoimmunity", Xianbixin's contribution is particularly prominent
.
According to reports, the company's research and development focus is mainly on the fields of tumor, nervous system and autoimmunity, and at the same time, it is forward-looking in the field of diseases that will have great influence in the future
.
Among them, in the field of nervous system, in addition to the two products of Xianbisin and Bicun, there are also Xianbexin sublingual tablets (a solid preparation composed of two active ingredients, edaravone and d-camphenol) under development.
expected
.
It is understood that the product can exert anti-inflammatory and improve the permeability of the blood-brain barrier through sublingual administration, thereby reducing the cranial nerve damage caused by acute ischemic stroke (AIS).
Sequential therapy is beneficial for patients to obtain a timely and complete course of treatment.
At the same time, sublingual tablets are not limited by medical site conditions and patient compliance, and are also more suitable for expanding other chronic central nervous system disease indications
.
As of the date of this announcement, the Group has nearly 60 innovative drug R&D pipeline projects and 19 innovative drug pipelines in the clinical stage, including 7 Phase III clinical trials, 5 Phase II clinical trials and 7 Phase I clinical trials
.
Among them, the conditional listing application of tralacil hydrochloride for injection has been submitted by the end of 2021 and has been included in the priority review; the progress of the phase III pivotal clinical trial of Xianbixin sublingual tablet has exceeded expectations, and it is expected to complete all enrollment in the first half of 2022 plan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
